Shop by goal
Popular compounds
Research resources
Recently viewed
Glow
Glow is a three-compound research blend combining GHK-Cu, BPC-157 and TB-500 in a single vial - the copper-binding tripeptide paired with the two most-studied tissue-repair peptides.
This strength is out of stock. Pick another strength, or check back soon — restocks are frequent.
Glow
Compare pack sizes
Tap a pack to select it in the purchase panel above
Buy the 10-pack - save 67%/mg
Single vials ship as an add-on to a 10-vial pack - browse 10-vial packs
Lab-direct quality — full packs or single-vial samples
Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.
Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same lab, same batch, same verified purity — scaled to whatever your research needs.
What It's Researched For
In plain terms, Glow puts three of the most-studied repair and skin peptides into one vial. Here is what that looks like across the research.
Matrix and collagen research
GHK-Cu is the copper-binding tripeptide studied for how skin builds and remodels its supporting matrix.
Tissue-repair signalling
BPC-157 and TB-500 are the two most-cited compounds in peptide tissue-repair research, studied for angiogenesis and cell migration.
Fewer handling steps
One vial, one reconstitution - instead of measuring and mixing three separate lyophilised powders.
Comparative work
Because all three components are sold separately, the blend can be benchmarked directly against its individual parts.
Overview
In short: Glow is a fixed research blend of GHK-Cu, BPC-157 and TB-500 - 70 mg of total peptide per vial, combining the copper tripeptide with the two most-studied tissue-repair compounds.
Key research facts
These points summarise lab themes, not human outcomes.
Glow is not a new compound. It is a fixed combination of three well-characterised research peptides that are routinely studied alongside one another: GHK-Cu at 50 mg, BPC-157 at 10 mg and TB-500 at 10 mg per vial. The rationale is practical rather than pharmacological - researchers working across matrix remodelling and tissue repair frequently reconstitute all three, and each additional powder is another weighing step and another chance to compound an error.
The components themselves have distinct and separately documented literatures. GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) first isolated from human plasma, studied for extracellular-matrix remodelling, collagen and decorin synthesis, and antioxidant gene signalling in dermal fibroblast models. BPC-157 is a synthetic pentadecapeptide derived from a sequence in human gastric juice, examined for angiogenic signalling and tissue-repair pathways. TB-500 is the synthetic analogue of the actin-binding domain of thymosin beta-4, studied for actin sequestration and cell migration.
What the blend does not have is a literature of its own. No pharmacokinetic or efficacy study exists for these three administered together as a fixed ratio, and combining them does not merge their half-lives or clearance routes. Treat Glow as a handling convenience over three separate compounds, not as a distinct entity. It is supplied as research-grade lyophilised powder for in-vitro and preclinical work only, and nothing on this page is medical advice.
Mechanism of Action
Glow has no combined mechanism - it is three independent research compounds sharing a vial. GHK-Cu acts through copper-complex matrix signalling, BPC-157 through angiogenic and growth-factor pathways, and TB-500 through actin binding. They are studied together because their research domains overlap, not because they act on a shared target.
The honest mechanistic account of Glow is that there is not one. Fixed-ratio peptide blends are a supply format, not a pharmacological class, and no study has characterised these three compounds administered together - no combined pharmacokinetics, no interaction data, no evidence for or against synergy. Each component brings its own profile: GHK-Cu is a small copper-complexing tripeptide with a well-documented dermal literature; BPC-157 is a pentadecapeptide whose stability in gastric conditions is unusual and whose angiogenic signalling is the subject of a large but predominantly rodent literature; TB-500 is a 43-residue-derived fragment acting through actin monomer binding. Researchers should design against the component literatures and treat the fixed 50:10:10 ratio as a constraint of the format rather than an evidence-based formulation.
Common Questions People Are Asking
What is in the Glow stack?
Each vial contains GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg - 70 mg of total peptide. The ratio is fixed across every vial in the pack. All three components are also available individually, so the blend can be benchmarked against its parts.
Why buy a blend instead of the three compounds separately?
Purely for handling. A fixed blend means one reconstitution step instead of three, which removes two weighing operations and the compounding error that comes with them. There is no pharmacological argument for the combination - the components retain their individual half-lives and clearance routes whether they share a vial or not.
Is there research on the three compounds used together?
No. No pharmacokinetic, safety or efficacy study has examined GHK-Cu, BPC-157 and TB-500 administered as a fixed blend, and no interaction data exists. The individual components have their own literatures - GHK-Cu's dermal and matrix-biology work is the most substantial - but component evidence does not transfer to a combination. Design protocols from the component literature.
How does Glow differ from Klow?
Klow is the same three compounds plus KPV at 10 mg, bringing the total to 80 mg per vial. KPV is the C-terminal tripeptide fragment of alpha-MSH, studied for anti-inflammatory signalling. Otherwise the GHK-Cu, BPC-157 and TB-500 quantities are identical between the two blends.
How should the Glow stack be stored?
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water or sterile saline, refrigerate at 1–6 °C and protect from light. Because the vial contains three compounds with different stability characteristics, use it within the validated window for the batch rather than extrapolating from any single component.
Where can I buy Glow?
Right here - Glow is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.
How much does Glow cost?
Glow pricing is shown live on this page, per pack size - 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $350.
Is Glow third-party tested?
Yes. Every Glow batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.
How do I buy Glow?
Add the Glow pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step. Every order ships with its batch Certificate of Analysis (COA).
What payment methods can I use to buy Glow?
At checkout you can pay by card or crypto. New-U supports BTC and selected stablecoin and network-asset payments across Ethereum, Solana, TRON, Polygon, Base, BNB Chain and Linea. You choose your method after confirming your order.
How fast is shipping, and do you ship worldwide?
Yes - we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.
Is it legal to buy Glow?
In the United States, Glow is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.
Research use only - all claims made on this site are for testing and research use only.
Pharmacokinetics
Evidence Tier
Overall: Tier 3: Anecdotal / self-report
Glow itself has no evidence base: no pharmacokinetic, safety or efficacy study has examined GHK-Cu, BPC-157 and TB-500 administered as a fixed blend, and no interaction data exists. The individual components are better supported - GHK-Cu in particular has a substantial dermal and matrix-biology literature - but component evidence does not transfer to a combination product. The blend has no regulatory approval in any jurisdiction and is supplied as unapproved laboratory material.
Certificates, databases & peer-reviewed sources
Last reviewed: 29 July 2026 · New-U Research Compounds
Key Characteristics
Specifications
About the Glow Stack: GHK-Cu, BPC-157 and TB-500 Research Blend Guide
Fixed peptide blends exist for a simple reason: reconstituting lyophilised powder is fiddly, and every additional vial in a protocol is another weighing, another diluent calculation and another opportunity to compound an error. Glow combines three compounds that researchers working in matrix remodelling and tissue repair frequently use alongside each other - GHK-Cu at 50 mg, BPC-157 at 10 mg and TB-500 at 10 mg, for 70 mg of total peptide per vial.
GHK-Cu carries the strongest independent literature of the three. It is a naturally occurring tripeptide (Gly-His-Lys) that complexes copper(II), first isolated from human plasma in the 1970s, and it has been studied extensively in dermal fibroblast models for extracellular-matrix remodelling, collagen and decorin synthesis, and antioxidant gene expression. BPC-157 and TB-500 come from a different tradition - both are heavily represented in rodent tissue-repair research, BPC-157 for angiogenic signalling and TB-500 for actin binding and cell migration - but neither has controlled human efficacy data.
The blend itself has no literature. No study has characterised these three compounds administered together, so there is no combined pharmacokinetics, no interaction data and no evidence bearing on whether the fixed 50:10:10 ratio is optimal for anything. New-U Research Compounds supplies Glow as a research-grade lyophilised powder with a batch certificate of analysis. All material is strictly for in-vitro and preclinical research use. It is not approved for human therapeutic use in any jurisdiction, and nothing on this page constitutes medical advice or a dosing recommendation.
Customer Reviews
No customer reviews yet - be the first to share your experience.
More in Stacks
Glow vs related Stacks compounds
Descriptive catalog comparison for research sourcing decisions - not dosing guidance.
More on Glow
From our community
What people say on Facebook
PRECISION. PURITY. PERFORMANCE.
Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.
Shop
Research
Support
Ways to Pay
Shop by goal
Shop by compound
Shop by region
Research use only - all claims made on this site are for testing and research use only. Purchasers must be 21 years of age or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io
[image: Glow research vial — Stacks compound supplied by New-U Research Compounds]